Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 24 articles: HTML format

Single Articles

September 2025
1. SCHOLTEN D, El-Shennawy L, Jia Y, Zhang Y, et al
   Double-positive T cells form heterotypic clusters with circulating tumor cells to foster cancer metastasis.
   J Clin Invest. 2025;135:e193521.
   PubMed     Abstract available
   
   
   August 2025
2. KIM S, Son E, Park HR, Kim M, et al
   Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer models.
   J Clin Invest. 2025 Aug 12:e188839. doi: 10.1172/JCI188839.
   PubMed     Abstract available
   
   
   
3. DEVARAJAN R, Izzi V, Peltoketo H, Rask G, et al
   Corrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
   J Clin Invest. 2025;135:e196478.
   PubMed    
   
   
   July 2025
4. ZHANG G, Jurinovic V, Bartels S, Christgen M, et al
   A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-responders.
   J Clin Invest. 2025 Jul 24:e177813. doi: 10.1172/JCI177813.
   PubMed     Abstract available
   
   
   
5. YANG Y, Chen C, Lyu Y, Gololobova O, et al
   HIF-1 promotes murine breast cancer brain metastasis by increasing production of integrin beta3-containing extracellular vesicles.
   J Clin Invest. 2025;135:e190470.
   PubMed     Abstract available
   
   
   
6. KALFEIST L, Ledys F, Petit S, Poirrier C, et al
   Co-targeting TGF-beta and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet.
   J Clin Invest. 2025;135:e184422.
   PubMed     Abstract available
   
   
   
7. SURESH S, Ford JM
   A triple-punch approach: methionine restriction enhances combination inhibitors in brain metastatic triple-negative breast cancer.
   J Clin Invest. 2025;135:e193171.
   PubMed     Abstract available
   
   
   
8. ZENG X, Zhao F, Tu X, Zhang Y, et al
   Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop.
   J Clin Invest. 2025;135:e188120.
   PubMed     Abstract available
   
   
   June 2025
9. BOSE M, Singh MI, Frodin M, Ejlertsen B, et al
   Precision screening facilitates clinical classification of BRCA2-PALB2 binding variants with benign and pathogenic functional effects.
   J Clin Invest. 2025;135:e181879.
   PubMed     Abstract available
   
   
   
10. THATTE J, Moises da Silva A, Borcsok J, Gudjonsson T, et al
    The class II myosin MYH4 safeguards genome integrity and suppresses tumor progression.
    J Clin Invest. 2025;135:e188165.
    PubMed     Abstract available
    
    
    May 2025
11. CHEN MK, Yamaguchi H, Gao Y, Xia W, et al
    FGFR3-induced Y158 PARP1 phosphorylation promotes PARP-inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models.
    J Clin Invest. 2025 May 29:e173757. doi: 10.1172/JCI173757.
    PubMed     Abstract available
    
    
    April 2025
12. YANG SY, Jin ML, Andriani L, Zhao Q, et al
    Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2- breast cancer.
    J Clin Invest. 2025 Apr 29:e183531. doi: 10.1172/JCI183531.
    PubMed     Abstract available
    
    
    January 2025
13. SAFAEE TALKHONCHEH M, Sjolund J, Bolivar P, Kurzejamska E, et al
    An Activin Receptor-Like Kinase 1-governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases.
    J Clin Invest. 2025 Jan 14:e183086. doi: 10.1172/JCI183086.
    PubMed     Abstract available
    
    
    November 2024
14. CAI Y, Liu CC, Zhang Y, Liu Y, et al
    MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.
    J Clin Invest. 2024 Nov 12:e183656. doi: 10.1172/JCI183656.
    PubMed     Abstract available
    
    
    
15. WU S, Zheng Y, Olopade OI
    The convergence of genomic medicine and translational omics in transforming breast cancer patient care.
    J Clin Invest. 2024;134:e187520.
    PubMed    
    
    
    October 2024
16. SINHA S, Callow BW, Farfel AP, Roy S, et al
    Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
    J Clin Invest. 2024;134:e170953.
    PubMed     Abstract available
    
    
    
17. KUMAR A, Goel H, Wisniewski C, Wang T, et al
    Neuropilin-2 expressing cells in breast cancer are S-nitrosylation hubs that mitigate radiation-induced oxidative stress.
    J Clin Invest. 2024 Oct 1:e181368. doi: 10.1172/JCI181368.
    PubMed     Abstract available
    
    
    September 2024
18. WINKLER J, Tan W, Diadhiou CM, McGinnis CS, et al
    Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes.
    J Clin Invest. 2024;134:e164227.
    PubMed     Abstract available
    
    
    
19. REEVES MQ
    Mapping the transcriptional evolution of human metastatic breast cancer.
    J Clin Invest. 2024;134:e183971.
    PubMed     Abstract available
    
    
    August 2024
20. SHEN Y, Yan J, Li L, Sun H, et al
    LOXL2-induced PEAR1 Ser891 phosphorylation suppresses CD44 degradation and promotes triple-negative breast cancer metastasis.
    J Clin Invest. 2024;134:e177357.
    PubMed     Abstract available
    
    
    May 2024
21. MARCHESE E, Demehri S
    Posttranslational protein modifications as gatekeepers of cancer immunogenicity.
    J Clin Invest. 2024;134:e180914.
    PubMed     Abstract available
    
    
    April 2024
22. JOHNSON N
    Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability.
    J Clin Invest. 2024;134:e179325.
    PubMed     Abstract available
    
    
    March 2024
23. ZHU Y, Banerjee A, Xie P, Ivanov AA, et al
    Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.
    J Clin Invest. 2024;134:e176390.
    PubMed     Abstract available
    
    
    January 2024
24. LUO M, Bao L, Xue Y, Zhu M, et al
    ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2.
    J Clin Invest. 2024;134:e171166.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.